Pieris Pharmaceuticals Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Pieris Pharmaceuticals te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei	28.4%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Jul 11

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

Apr 21

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Mar 19

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

Dec 18

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Aug 18

Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

May 15

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Apr 17

Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Dec 31

Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Aug 10

Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M

Aug 04

Pieris: Early Stage Developer Of Novel Asset Class

Jan 09

We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Dec 15

Progress At Pieris Pharmaceuticals

Oct 27

Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

Aug 05

We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 19

Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

May 22

Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

May 19

Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Apr 01

Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

Mar 08

We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Feb 01

How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Dec 28

How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?

Dec 02

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Pieris Pharmaceuticals onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

NasdaqCM:PIRS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
9/30/2024	1	-16	-28	-28	N/A
6/30/2024	21	-24	-38	-38	N/A
3/31/2024	41	-16	-50	-50	N/A
12/31/2023	43	-25	-54	-54	N/A
9/30/2023	47	-28	-47	-47	N/A
6/30/2023	33	-27	-46	-46	N/A
3/31/2023	17	-41	-49	-48	N/A
12/31/2022	26	-33	-61	-60	N/A
9/30/2022	28	-35	-59	-58	N/A
6/30/2022	27	-42	-65	-64	N/A
3/31/2022	27	-47	-19	-18	N/A
12/31/2021	31	-46	-9	-8	N/A
9/30/2021	25	-51	-11	-10	N/A
6/30/2021	24	-48	-3	-3	N/A
3/31/2021	32	-38	-44	-43	N/A
12/31/2020	29	-37	-49	-46	N/A
9/30/2020	45	-26	-50	-46	N/A
6/30/2020	57	-15	-56	-52	N/A
3/31/2020	51	-22	-57	-52	N/A
12/31/2019	46	-28	-55	-52	N/A
9/30/2019	34	-36	-49	-48	N/A
6/30/2019	27	-40	-51	-49	N/A
3/31/2019	33	-28	-49	-48	N/A
12/31/2018	29	-27	-3	-1	N/A
9/30/2018	42	-8	1	3	N/A
6/30/2018	38	-8	N/A	53	N/A
3/31/2018	28	-18	N/A	55	N/A
12/31/2017	25	-18	N/A	50	N/A
9/30/2017	10	-32	N/A	48	N/A
6/30/2017	7	-31	N/A	9	N/A
3/31/2017	6	-27	N/A	9	N/A
12/31/2016	6	-23	N/A	-14	N/A
9/30/2016	5	-19	N/A	-10	N/A
6/30/2016	5	-17	N/A	-10	N/A
3/31/2016	4	-15	N/A	-7	N/A
12/31/2015	3	-14	N/A	-13	N/A
9/30/2015	4	-15	N/A	-10	N/A
6/30/2015	4	-13	N/A	-8	N/A
3/31/2015	4	-13	N/A	-8	N/A
12/31/2014	5	-10	N/A	-5	N/A
9/30/2014	6	-5	N/A	-6	N/A
12/31/2013	12	0	N/A	-3	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van PIRS boven de spaarquote ( 2.6% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van PIRS naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van PIRS naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van PIRS naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van PIRS naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PIRS naar verwachting over 3 jaar hoog zal zijn

Pieris Pharmaceuticals Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates fall by 31%

Price target decreased to US$7.00

Consensus revenue estimates fall by 48%

Consensus estimates of losses per share improve by 23%

Consensus revenue estimates increase to US$32.5m

Price target increased to US$8.50

Recent updates

Third quarter 2024 earnings released: US$2.19 loss per share (vs US$8.70 loss in 3Q 2023)

Pieris Pharmaceuticals, Inc., Annual General Meeting, Dec 02, 2024

Second quarter 2024 earnings released: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023)

Palvella Therapeutics, Inc. agreed to acquire Pieris Pharmaceuticals, Inc. (NasdaqCM:PIRS) in a reverse merger transaction.

New major risk - Share price stability

The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

First quarter 2024 earnings released: US$3.96 loss per share (vs US$14.15 loss in 1Q 2023)

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

Pieris Pharmaceuticals Approves 1-for-80 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.27 loss per share (vs US$0.45 loss in FY 2022)

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pieris Pharmaceuticals, Inc. Announces Executive Changes

New major risk - Financial position

New major risk - Share price stability

Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

Consensus revenue estimates fall by 31%

Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.069 loss in 1Q 2022)

Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Review for 10 Mg Dose of Phase 2A Trial of Elarekibep (Prs-060/Azd1402)

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Full year 2022 earnings released: US$0.45 loss per share (vs US$0.71 loss in FY 2021)

Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346)

Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Price target decreased to US$7.00

Insufficient new directors

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Pieris Pharmaceuticals, Inc. Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

Consensus revenue estimates fall by 48%

Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pieris Pharmaceuticals, Inc. Announces Tim Demuth Steps Down as Senior Vice President and Chief Medical Officer, Effective September 30, 2022

Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 23%

Pieris Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2022

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Pieris: Early Stage Developer Of Novel Asset Class

Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2A Trial of PRS-060/AZD1402

We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2020)

Insufficient new directors

Progress At Pieris Pharmaceuticals

Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.095 loss in 2Q 2020)

Consensus revenue estimates increase to US$32.5m

Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

Price target increased to US$8.50

Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth Index

We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Consensus revenue estimates fall to US$22.0m

Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

Price target decreased to US$7.50

Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

First quarter 2021 earnings released: US$0.074 loss per share (vs US$0.065 loss in 1Q 2020)

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.56 loss in FY 2019)

Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Pieris Pharmaceuticals, Inc. announced that it expects to receive $10.000002 million in funding from AstraZeneca PLC

Pieris Pharmaceuticals, Inc. announced that it has received $13.008671 million in funding

New 90-day low: US$2.41

Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

New 90-day high: US$3.19

We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Price target raised to US$9.00

How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

New 90-day high: US$3.13